EXHIBIT 99

             ONCOLOGIX TECH PROVIDES GUIDANCE ON ONCOSPHERE PROJECT
                             MILESTONES AND TIMELINE


SUWANEE, Georgia.--(Marketwire) November 26, 2007 - Oncologix Tech Inc. (OTC BB:
OCLG.OB) announced today that it completed animal studies, with rabbits,
fulfilling four of the six objectives needed for the FDA IDE submission and will
need to test the Oncosphere with another animal model to demonstrate the final
two objectives. Additionally, Oncologix Tech announced that it intends to apply
for ISO certification and CE Mark to allow for commercialization of the
Oncosphere in the European Union in 2008.

The purpose of the animal studies is to (i) evaluate the functionality of the
system, (ii) evaluate the ability to deliver of the microspheres with
fluoroscopy (x-ray), (iii) evaluate the distribution of microspheres in the
liver and other organs, (microsphere deposition patterns, cluster analyses, and
location of implantation in liver tissue), (iv) evaluate the ability to image
the microspheres post-delivery, (v) evaluate the bioavailability of free and/or
bound Y-90 and In-111 (radiation) in the first 30 days in body fluids, and (vi)
evaluate the effects of the microspheres and radiation on the liver, adjacent
tissues, and possible target organs in the first 90 days.

The first four of the six objectives were met during the animal studies. Most
importantly, the studies demonstrated the ability to image the microspheres
post-placement. Management believes that by fulfilling these objectives,
Oncologix has confirmed the ability of the Oncosphere, to be delivered, imaged
in the liver, and subsequently analyzed for post-planning purposes. The
remaining two objectives were not satisfied with the rabbit studies because the
structure of the rabbit anatomy does not provide an adequate representation of
human anatomy to evaluate the Oncosphere for the two remaining objectives. The
blood vessels of the rabbit are too short and too close to the blood vessels of
the intestine and stomach to prevent the microspheres from being injected into
other vessels making it impossible to evaluate these final objectives. The
Company intends to continue the studies with another animal whose anatomy more
closely resembles human anatomy than the anatomy of the rabbit.

The completion of this additional study will require funding in a greater amount
than now budgeted (up to $1,200,000, which includes the costs to allow European
commercialization) and an additional four to six months to design, qualify, and
complete. Successful completion of the additional studies would support an
application for FDA approval of the first treatment of patients on an
experimental basis early in the second half of 2008.

Andrew Green, President and CEO of Oncologix stated, "We have been excited by
the results of the imaging studies and the response to these results by
physicians and physicists at the American Society for Therapeutic Radiology and
Oncology conference in Los Angeles last month. We are confident that we will be
able to complete the remaining objectives in a timely manner and move forward
with the IDE submission to the FDA in the first half of 2008."

Additionally, Oncologix Tech announced that it is in the process of selecting a
notified body (approving authority) in the European Union to allow the
application for ISO certification (Quality System approval) and CE Mark




application (approval for commercial sale in Europe) that will allow commercial
distribution of the Oncosphere in Europe. Oncologix anticipate that the approval
to distribute could be obtained before the end of 2008, demonstrating the
commercial and clinical viability of the Oncosphere product.

Mr. Green went on the state, "Entry into the European market would be a powerful
step for Oncologix. The European market has always been an early adopter of new
technologies and will give Oncologix the ability to develop and test the
logistical aspects of our operations, while providing a beneficial treatment to
patients in the region."

About Oncologix Tech Inc. and its subsidiary, Oncologix Corporation.:
- ---------------------------------------------------------------------
Oncologix Tech Inc., (formerly BestNet Communications Corp.) was formerly a
provider of long distance telephone communication services but disposed of that
business in January 2007.

The Company is developing a brachytherapy (radiation therapy) device, the
Oncosphere System, for the advanced medical treatment of soft tissue cancers. It
is based on a radioactive microparticles designed to deliver therapeutic
radiation directly to a tumor site by introducing the microparticles into the
artery that feeds the tumor tissue.

This release contains forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, which are intended to be
covered by the "safe harbor" created thereby. These statements include the plans
and objectives of management for future operations, including plans and
objectives. The forward-looking statements herein are based on current
expectations that involve judgments with respect to, among other things, future
economic, competitive and market conditions and future business decisions, all
of which are difficult or impossible to predict accurately and many of which are
beyond control of the company. Although the company believes that the
assumptions underlying the forward-looking statements are reasonable, any one of
the assumptions could be inaccurate and, therefore, can be no assurance that the
forward-looking statements included in this release will prove to be accurate.

Contacts:
Andrew Green
Chief Executive Officer
Tel: (770) 831-8818

Michael Kramarz
Chief Financial Officer
Tel: (616) 977-9933

                                      # # #